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Abstract
Influenza vaccination coverage in countries of Latin America is low among priority risk
groups, ranging from 5 to 75% among older people. This paper aims to describe and ana-
lyze the determinants of influenza vaccination hesitancy through the lens of the 3C model of
confidence, complacency and convenience among middle-class, urban risk group popula-
tions in Brazil, Chile, Paraguay, Peru, Uruguay, countries in South America with contrasting
vaccination coverage. Focus groups were conducted among four risk groups: pregnant
women, mothers of children aged <6 years, adults with risk factors, and adults aged�60
years in samples of urban residents. Adults with risk factors expressed the most detailed
perceptions about confidence in the vaccine. A wide range of perceptions regarding compla-
cency were expressed across risk groups and countries, with pregnant women and mothers
showing greater concerns while convenience had a narrower and generally more positive
range of perceptions. Participants from Chile and Paraguay expressed the most contrasts
regarding confidence and complacency. Information and communication strategies need to
be tailored for risk groups while confidence and complacency should be addressed in
synergy.
Introduction
Influenza is a respiratory viral disease whose symptoms can be confused with those of a com-
mon cold, easily escalating to a more serious condition and even leading to death. Influenza
cases are estimated at around 1 billion per year worldwide, of which 3 to 5 million are severe.
Modelling studies suggest between 291 243 and 645 832 influenza deaths occur annually [1].
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H1N1 influenza spread out with particular force in South America, registering over 2.6 million
cases in 2009 and particularly affecting Argentina, Brazil and Chile with over 600 thousand
estimated cases in each country [2].
According to the World Health Organization, vaccination is the most effective measure to
prevent influenza infection [3]. However, vaccine efficacy was low at first, with figures below
60% across age groups and among older adults ranging from 9 to 60%. Vaccine efficacy
increased above 60% with the introduction of the high dose vaccine, reducing mortality by up
to 80% [4]. Influenza vaccine has been reported with up to 90% of effectiveness in the case of
healthy adults, while in older adults, effectiveness can be of 60%, reducing mortality by up to
by 80% [5]. Most Latin American countries influenza vaccination policies mandate it for chil-
dren aged under 6 years, people with chronic comorbidity, adults aged over 60 years, pregnant
women within 20 weeks of gestation, or women in the postpartum period [6]. Yet countries in
the region have ample opportunity to increase coverage. In the countries comprised by Brazil
and those in the Andean Region and the South Cone, average vaccination coverage in 2018 for
older adults ranged from 5 to over 75%, with an average of 61.6%. Among children under six
years of age, average coverage was 58.4% and 56.7% for pregnant women and 76.7% for adults
with chronic conditions [7]. Coverage in Argentina, Bolivia, Brazil, Chile, Colombia and Ecua-
dor is above average when considering all risk groups, while coverage in Paraguay, Peru, Uru-
guay and Venezuela is below average.
The decision-making process followed by the population to get vaccinated is immersed in a
specific social context of beliefs and perceptions as well as considerations of the availability of
the vaccine and its costs. Mistrust and doubts about the safety and efficacy of the seasonal
influenza vaccine represent one of the main barriers to vaccination in various world regions
and constitutes a threat to vaccination programs [8, 9]. Divergence of vaccination uptake
across countries in South America attests to the importance of analyzing the role that diverse
supply and demand factors play.
The World Health Organization’s Strategic Advisory Group of Experts proposed the con-
cept of vaccine hesitancy with the objective of analyzing the social factors that lead either to a
delay in the acceptance or to the rejection of vaccines despite availability of vaccination ser-
vices [10]. Vaccine hesitancy is the result of a complex interaction of behavioral and societal
factors whose intervention requires an integral approach. Different conceptual models have
been proposed to address the complexity, applicability, and potential usefulness of vaccine hes-
itancy indicators, as well as for the design of surveys and interventions that can be applied
locally and globally [11]. The “Three Cs” model of vaccine hesitancy analyzes three groups of
determinants: confidence, complacency, and convenience, and has been considered as one of
the most useful models of vaccine hesitancy given that it is intuitive and easy to understand
and apply. This model is derived from the sociomedical literature and is complete as well as
simple, allowing us to understand the complex vaccination decision-making process [12].
Confidence is the degree of trust in the effectiveness and safety of the vaccine, in the system
that delivers the vaccines–including the reliability and competence of the health services and
health professionals–, and in the motivations of those who make the decisions to achieve effec-
tive access to the vaccines [10]. Lack of confidence is caused by strong negative attitudes
towards vaccination, which can be influenced by misinformation about vaccination risks, by
affiliation to anti-vaccine groups or through legitimate concerns regarding vaccine safety and
efficacy.
Complacency refers to the degree to which people consider vaccination necessary to pre-
vent a vaccine-preventable disease and is the result of a combination of risk perception, knowl-
edge of the disease and of the vaccine and of prejudices relating to side effects and other
reactions, and of the need for vaccination. Complacency is influenced by the relative priorities
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assigned to health as against other responsibilities and may stem paradoxically from a lowering
of risk perception due to immunization program success. Self-efficacy–the self-perceived or
real ability of an individual to take action to vaccinate–also influences the degree to which
complacency determines hesitancy.
Convenience of the vaccine is defined by availability, affordability, willingness-to-pay,
geographical accessibility, ability to understand and accept vaccine-related information (lan-
guage, culture and health literacy), the appeal of immunization services, and quality of care
[13].
This paper aims to describe and analyze the determinants of influenza vaccination hesi-
tancy through the lens of the 3C model across urban risk groups in five Latin American
countries with contrasting coverage levels, selecting Brazil and Chile as high coverage
countries and Paraguay, Peru and Uruguay as low coverage countries. Countries with dif-
ferent coverage rates were selected to identify the fullest possible range of expressions of
confidence, complacency and convenience and to discuss their implications for vaccine
uptake.
Methods
The protocol was reviewed by authorized ethics committees within each of the study countries,
as follows: Brazil, Comissão Nacional de Ética em Pesquisa, 05215918.6.0000.5347. Chile:
Comité de Ética de Investigación en Seres, Universidad de Chile, Facultad de Medicina, 191–
2018. Paraguay: Comité de ética en Investigación, Laboratorio Central de Salud Pública, 106/
2019. Peru: Comité de Ética de Investigación Prisma, CE1651.18. Uruguay: Comité de Ética en
Investigación, Instituto Nacional de Salud Pública, 1580.
The study design is multi-center and qualitative, contrasting knowledge, attitudes and prac-
tices through focus group technique with homogeneous members of four risk groups. Focus
group methodology was chosen over other techniques to address the qualitative aspects of vac-
cine hesitancy given its capacity to obtain a greater amount of information in a shorter time
elicited both through directed queues and the interaction between participants [14]. Further-
more, focus groups would enable us to obtain a first repertoire of perceptions on the basis of
which to later address the hesitancy through more structured instruments. Interaction
between persons sharing risk group characteristics would elicit the widest possible range of
views based on knowledge, beliefs and practices regarding influenza vaccine confidence, com-
placency and convenience.
Focus groups were evenly distributed in one or two large cities within each country as fol-
lows Brazil: Porto Alegre (in the state of Rio Grande do Sul); Chile: Santiago and Valparaı́so;
Perú: Arequipa and Lima; Paraguay: Asunción and Ciudad del Este, and Uruguay: Montevideo
and Salto (Table 1). Participants across the four risk groups lived in lower-middle class neigh-
borhoods. A representative survey of health facility clients in the same neighborhoods under-
taken as a part of the same research project to explore quantitative determinants of vaccine
hesitancy showed that between 26.9 and 38.8% of elderly adults and adults with risk factors,
respectively, had up to primary education, as against pregnant women and mothers of chil-
dren, among whom only between 8.1 and 9.3% had such lower education levels. Participants
from Paraguay and Uruguay tended to have lower education levels across risk groups when
compared to participants from the other countries [15].
Focus groups were piloted and initiated in Peru in October 2018 and followed up in the
four other countries between March and July of 2019, as soon as ethics committee authoriza-
tions allowed, and aiming to hold them as close as possible to influenza immunization cam-
paigns. Table 1 describes the focus group recruitment strategy and characteristics. Individuals
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with homogeneous characteristics were recruited based on having the attributes of each of the
following risk-groups: adults above 60 years of age (OA), adults with risk factors (ARF), preg-
nant women (PW) and mothers of children under 6 years of age (MC). Focus groups had
between 6 and 10 participants with an average of 8, recruited upon leaving health facilities in
the case of Brazil, Paraguay and Peru. In Chile, participants were recruited based on a sample
frame developed for research purposes and registering risk group attributes and socioeco-
nomic characteristics. In Uruguay, recruitment was based on a Facebook call, filtering for risk
group and health service use characteristics. Heterogeneity within focus groups was sought
with respect to the vaccination decision (accepted and declined) in order to understand in-
depth, the reasons and influences in both cases, as well as the obstacles and facilitators that led
to their choice. Focus groups were undertaken in Spanish or Portuguese for the case of Brazil.
All participants spoke Spanish or Portuguese and no translation was required. Focus groups
were moderated in all cases by an expert focus group researcher, supported by an observer.
Focus groups were held in meeting rooms or open spaces within or next to health facilities in
Table 1. Focus group participants by country and risk group.
Country and
date
No. of focus groups by
recruitment strategy (and
risk group)












4 Pub Health services’ meeting room Total 33 90 None
OA 9 8-1/ 71
ARF 8 6-2/ 71
PW 7 7/ 35
MC 9 9/ 34
Chile, May
2019
4 OS Researchers’ meeting room Total 30 85 USD 20 gift card
OA 8 4-4/ 69
ARF 8 5-3/ 47
PW 6 6/ 27
MC 8 8/ 33
Paraguay,
March 2019
1 Pub (MC) Pub: Within health services; Priv:
Hotel meeting room & researchers’
meeting room
Total 29 90 Umbrella and
toiletry bag’3 Priv (OA, ARF, PW) OA 7 4-3/ 68
ARF 9 8-1/ 50
PW 7 7/ 26




3 Pub (OA, ARF, PW) Pub: open air meeting place in park
near health services except for PW,
held in meeting room.
Total 25 90 Diapers only for
PW1 Priv (MC) OA 7 6-1/ 71
ARF 6 4-2/ 42
PW 6 6/ 27
Priv: health services’ meeting room MC 6 6/ 35
Uruguay, July
2019
4 OS Researchers’ meeting room Total 33 90 USD 27 gift card
OA 7 4-3/ 68
ARF 9 8-1/ 49
PW 7 7/ 31
MC 10 10/ 35
Pub: Public services; Priv: Private services; OS: Other Strategy (Facebook call or researchers’ contact network); OA Older adults; ARF: Adults with Risk Factors; PW:
Pregnant Women; MC: Mothers of children.
https://doi.org/10.1371/journal.pone.0256040.t001
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Brazil, Paraguay (one focus group) and Peru, and in research meeting rooms or a hotel meet-
ing room in Chile, Paraguay (three focus groups) and Uruguay.
A discussion guide was developed and organized into knowledge, attitudes and practices
sections including each the discussion of vaccine confidence, influenza complacency and vac-
cine convenience. (The guide is available as a S1 File). Within each section. Focus group ses-
sions were audio-recorded after verbal informed consent was obtained from participants and
information was transcribed verbatim. A first code list was developed by two of the authors
(BP and MAGB) based on the theoretical framework and the pilot study focus group data
from Peru. A coding manual was provided to researchers within countries (YC, PC, AFL, LB,
DRK, BR and MR). Codes were inductively refined and detailed by country-level researchers
based on focus group data. Detailed codes were reviewed by BP to arrive to a final set of codes
for each country. Country data codification was reviewed by BP, DRK, AFL and disagreements
involving the allocation of statement to the categories of confidence or complacency were
resolved by consensus. Information was encoded with the support of the Atlas-ti v.8 software.
Qualitative content analysis was carried out on thematic units of analysis based on the 3 Cs
model categories by each of the country researchers. The main focus of analysis were risk
groups, followed by cross-risk group analysis. Country case studies were produced by country-
level researchers and reviewed by BP and MAGB. Final interpretation was based on comparing
country case studies.
Results
Tables 2–4 present an overview of the range and contrast in perceptions regarding confidence,
complacency and convenience by risk group.
Confidence: Effectiveness of the vaccine
The group of older adults and, to an extent, adults with risk factors showed a wide range of
positive evaluations on the effectiveness of vaccines, including the recognition of the impor-
tance that vaccines be effective and a more nuanced perception of vaccine potential and limita-
tions. As shown in Table 2, perceptions range from a clear sense of vaccine effectiveness,
including limitations, lack of reliability, and a perception of trust or distrust in the context of
negative experiences:
I always got the flu, I felt really terrible. My relatives would call me and say “but it’s not possi-
ble that you have the flu again. Take vitamin C” After I started taking the vaccine, I never got
worried about the flu again, nor even of a cold.
(OA, Brazil).
I have been vaccinated and [yet] I caught a cold, but [it was] milder (. . .) but I still trusted the
vaccine.
(OA, Chile).
I don’t know for sure, but I’ve heard that in the USA nobody takes the vaccine, because they
say that the vaccine is to make more people have the flu.
(ARF, Uruguay)
In spite of perceiving influenza as a grave threat, the appreciation of effectiveness is ambiva-
lent across risk groups, as attested by mothers:
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I don’t trust it entirely. People say that if you have the flu you can die. . . then there are those
who take it [the vaccine] and you can still end up really sick. Then there are those who don’t
take it [the vaccine] and who don’t get sick.
(MC, Brazil).
Table 2. Thematic analysis of confidence by risk group across the five countries.
Category/
Group
Older adults Adults with risk factors Pregnant women Mothers of children
Effectiveness of
vaccine
• Vaccine is trusted and accepted
as key preventive action
• Vaccine known to be effective
• Compliance during campaigns
associated with trust in the
vaccine
• May accept vaccination in spite
doubts about efficacy
• Influenza is contracted even
after vaccination
• Clear concept of vaccine efficacy
• All vaccines are only partially
effective
• Vaccine effectiveness widely
shared
• Vaccine is not reliable,
inefficacious
• Doubts on efficacy
• Trust clearly associated with
positive experiences
• Some trust in spite of negative
experiences
• Feel protected by vaccine
• Distrust when negative
experiences perceived
• Few express trust
• Benefit of vaccine is
prevention of influenza
• Question vaccine efficacy, but
no serious side-effects
• Adequate, timely information
leads to trust, even when there
are side effects
• Vaccination experience related to
perceptions of efficacy
• Vaccine is controversial
• Doubts on range of influenza strain
protection
• The more specific information is
available, the more trust
Safety of
vaccine
• Vaccine can weaken capacity to
fight influenza
• Vaccine known to be safe
• Vaccine associated with
allergies and reactions
• Fear of getting sick leads to
reject vaccination
• May accept vaccination in spite
doubts about safety
• Misinformation can blur safety
concerns
• Low information related to low
trust
• The vaccine can cause influenza
• Vaccine safety widely shared
• Doubts on safety
• Vaccine rejected to avoid mild
side effects: Fever and cold
• Vaccination during a respiratory
episode can be harmful
• Fear of needles
• Fear that the vaccine is expired
• Information demanded on
adverse side effects and on their
impact on comorbidities
• Do not have a clear
understanding of disease
• Vaccine rejected out of fears
of health consequences for
baby
• Discomfort and pain typical
of virus inoculation
• Vaccine perceived as not
natural and potentially
harmful
• Vaccine can cause the disease
• Vaccination experience related to
perceptions of safety
• Little knowledge about influenza
and the vaccine
• Mercury in the vaccine perceived as
autism risk
• Information on influenza and the
vaccine demanded, as specific as
possible
• Lack of information during
vaccination campaigns
• Face-to-face to information at
health centres is valued
Trust in health
system
Doubts due to varying vaccine and
disease names
• Vaccine perceived as reliable,
especially if administered in
health facilities
• Yet institutions can be
mistrusted
• Information mostly sought
from health providers
• Annual vaccination can prevent
influenza
• Distrust related to insistence on
repeating vaccination annually
• Trust associated with medical
advice and to trust in health
institutions
• Higher quality of vaccine in the
private sector
• Knowledge given by physicians
is trusted
• Satisfaction with information
available
• Distrust due to opaque interests
of vaccine producers
• Main sources of information are
health providers and during
campaigns
• Trust as an "act of faith" in
health system
• Doubts due to varying vaccine
and disease names
• Confidence in medical
referrals and health providers
• Question the need for
vaccination, even if
prescribed
• Health team is main source of
information
• Strong adherence to child
vaccination schedules
• Journalists on TV and the press
introduced fears of vaccination
• Health team and personal
experience are more important
sources of information than
campaigns
https://doi.org/10.1371/journal.pone.0256040.t002
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Mothers more than other groups expressed the need for specific information on vaccine
effectiveness to enhance their trust:
I think more information is needed. I do not get carried away by people, of what they are say-
ing. I think you have to trust, and you have to get informed, that the doctor explains [the
Table 3. Thematic analysis of complacency by risk group across the five countries.




• Influenza is a "a more serious flu",
easily transmitted, with more intense
symptoms, which can result in
complications and death
• No clear definition of influenza;
confusion with dengue
• Influenza is serious and potentially
mortal but treatable; needs care and
medication
• Perception of risk severity related to
experience of contagion by self or close
contacts
• Severity also perceived from mass
media
• All the population has same risk of
contracting influenza
• Everyone can get sick, but older adults
get worse
• Elderly are special risk group
• Grandchildren more at risk
• Influenza is vaccine preventable
• Not a treatable disease; it has to be
overcome
• Importance of timely medical care
• Influenza perceived as "more
intense" flu varying according
to person’s state of health
• Influenza is a dangerous,
potentially mortal disease
• Influenza can lead to
complications of pre-existing
illness
• "Low defenses" favor influenza
• Relationship with pre-existing
risks not always recognized
• Influenza is a serious and
potentially mortal disease
• Influenza symptoms similar,
but stronger, than those of
common cold or flu
• Influenza is a complication
of respiratory diseases
• Ignorance of disease
symptoms
• Confusion with dengue and
swine flu
• Influenza not a serious
disease
• Highly infectious among the
general population
• Pregnancy not a risk for
influenza
• Older adults and children
more at risk
• A preventable disease
• The vaccine lasts for several
years
• Can be cured by health
providers
• Influenza is a normal disease
in childhood
• Influenza is a "strong flu"
• A severe, potentially mortal
disease
• Severity is learned from close
contacts
• Influenza symptoms are
similar to flu, but stronger
• Influenza is a complication of
a respiratory process
• Influenza caused by climate
change and exposure to cold
• Everyone is equally exposed
• Children more exposed due
to behavior
• People more at risk are those
suffering other diseases,
pregnant women and older
adults
• A treatable disease by doctors





• Multiple prevention methods
• Vaccine is the socially validated main
prevention method
• Principal prevention methods are
hygiene, diet and home remedies
• Fear of injections an important reason
to reject vaccine
• Hygiene and health foods with vitamin
C can prevent influenza
• Multiple prevention methods,
but vaccine is best
• Hand washing and wearing
face masks more important
than the vaccine
• Vaccination is the main form
of prevention when influenza
is perceived as important




• A healthy person better avoid
the vaccine and its secondary
effects
• Existence of the vaccine is
well known
• Vaccine is one among other
preventive measures
• Healthy pregnancy does not
require vaccination
• Influenza can be prevented
hygiene and a good diet with
vitamin C
• Avoiding contact with sick is
important (sharing utensils)
• Vaccine not demanded if not
prescribed by doctor
• Vaccine is one among other
preventive measures
• Vaccinate avoided if
hygienic-dietetic measures
practiced
• Vaccine complementary to
healthy diet
Self-efficacy • Important to know cases of diseases
and how to prevent it
• Demand information on severity
• Information on adverse side effects is
demanded
• Demand information for early
detection
• Information about the disease,
vaccine and its side effects is
demanded
• Vaccine is important given
medicine contraindications
during pregnancy
• Information about the
disease, disease prevention
and the vaccine is demanded
• Knowledge demanded on
the impact of vaccine on
baby





schedule/passbook up to date
is an incentive
https://doi.org/10.1371/journal.pone.0256040.t003
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Table 4. Thematic analysis of convenience by risk group across the five countries.




• High availability of vaccine
• Vaccination more frequent during
campaigns
• Easy access to health centers, both
public and private
• Health facilities and mobile posts
provide vaccine during campaign
• Good proximity
• Options at municipal level
• All posts open regardless of health
coverage
• Not known which services treat
influenza
• Vaccine can be bought in pharmacy
for home application
• Vaccines are always available at public
and private health centers
• Easy access to health centers for
vaccination, both public and
private
• Ease of being vaccinated in
campaigns
• Vaccine not always available
• Diversity of vaccination centers
(hospitals, polyclinics, state
institutions, mobile)
• Know which health services treat
the disease
• Persons outside priority risk
groups have difficulties in
accessing
• Neighborhood councils offer
vaccination
• Health facilities nearby
• All posts open regardless of
health coverage
• Vaccine can be bought in
pharmacy for home application
• Vaccination only during
campaign
• Medical care received for pre-
existing diseases facilitates access
to influenza information
• Easy access to health
centers for vaccination,
both public and private
• Ease of access, even after
campaign ends
• Vaccine not always
available




• All posts open regardless
of health coverage during
the campaign
• Good access to public and
private health centers in
metropolitan area
• Closeness to health
facilities
• Vaccine applied in
prenatal care
• Vaccine can be bought in
pharmacy for home
application
• Vaccination in the
campaign
• Do not know where and
when to get vaccinated
• Difficult access to health
facilities due to closures
• Lack of vaccines in some
health facilities
• Easy access to health
centers for vaccination,
both public and private
• Know where to vaccinate
children
• Educational institutions
and mobile vaccines units
identified
• Vaccine only available
during campaigns
• No consensus on the
availability of the vaccine
• Good access to public and





• Easy access to vaccination
posts
• Closeness to health
facilities
• Vaccine can be bought in
pharmacy for home
application
• Difficult to travel with
children




• Free public health system used
• Vaccines can be expensive in private
services
• Free access • Free access
• Those who were
vaccinated outside




• Self-perceived as a privileged group in
campaigns
• Insufficient information
• Insufficient information on campaigns
• Feel a strong link with the health
service
• Feel satisfied with knowledge on
vaccine and the flu
• Everyone knows where to get
vaccinated
• They are well linked to health





• Lack of information about
campaigns
• Do not participate in
vaccination campaigns
• Media and close contacts
are sources of information
• Information on
prevention from TV and
social networks
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All groups expressed, paradoxically, that the vaccine is safe and that it has risks of its own.
Except pregnant women, informants of all risk groups expressed concerns that the vaccine
may be ineffective and cause adverse reactions:
I was vaccinated the first year that the influenza vaccine came out, but that year was the
worst in my life, . . . it gave me a fever, then for the following year, my daughter-in-law. . . said
"we are not going [to vaccinate] you”. . . I will never get that vaccine again. . . apparently it
does not suit me.
(OA, Paraguay).
Aspects such as fear of needles, the adduced presence of mercury and its relations to autism,
and ignorance on side effects the vaccine can have on babies contribute to raising doubts
about safety. One mother from Chile with experience of pre-term births expressed having to
be particularly careful in case contaminated vaccines cause autism:
In the last resort, I prefer that [vaccines] be mercury-free. . . because I know of cases of people
with autism who associate it with that.
(MC, Chile).
Mothers and pregnant women also expressed concern with potential side effects from the
vaccine:
Table 4. (Continued)
Category/Group Older adults Adults with risk factors Pregnant women Mother under 5 years old
Quality of service &
cultural
appropriateness
• Vaccination is fast
• Main source of information are health
providers
• Positive evaluation of vaccination at
public and private health centers
• Attention is prompt and friendly
• Vaccination is often late
• Conflict between vaccination and
cultural perceptions of state of being
(the vaccine must be applied without
being “cold”)
• Vaccination information comes from
health centers, mass media
(vaccination campaigns).
• Excellent treatment from service
providers
• Good treatment in health care in
services and campaigns
• Positive evaluation of
vaccination at public and private
health centers
• Attention is prompt and friendly
• Vaccination information comes
from health centers, mass media
(vaccination campaigns).
• Satisfaction with the treatment
and prompt attention
• Positive evaluation of
vaccination at public and
private health centers





• Good treatment at the
vaccination center
• Prenatal check-ups as
main source of
information
• Positive evaluation of
vaccination at public and
private health centers
• Attention is prompt and
friendly
• Vaccination information
comes from health centers
• Barriers to treatment
• Personnel need training
• Cultural barriers.
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I think that the vaccination campaigns. . . on television, are informative but superficial. [They
should be] more in-depth [stating] side effects, [how to] differentiate the flu from a common
cold, at what point to get the vaccine if you have a cold. The information on TV is about how
to get the vaccine, get vaccinated, but why, or for what benefits, that I think is lacking.
(MC, Chile).
Confidence: Trust in the system
Confidence in the information offered by service providers varies across risk groups. Confu-
sion with the wide range in vaccine nomenclature i.e. “H1N1”, “influenza”, “swine flu” was
widely shared. All groups also expressed the need to have more, and more specific, informa-
tion on influenza and on the vaccine.
It’s like a mutation from the common flu. It was called the swine flu. I do not know very well
how it started and each time it comes back, it is as if it continues to mutate. There’s the H1N1
and I think there are other letters, there are several. Actually, that was the one that affected
the most.
(MC, Uruguay).
Adults with risk factors expressed the most nuanced notions of trust (or distrust) with the
health system, both as a whole and with vaccination services and campaigns specifically. The
fact that influenza vaccination schedule needs to be updated every year engenders mistrust
regarding the vaccine’s effectiveness.
My boss works in health and says that every year the strains change, yet when the vaccine
comes here it is [with] the old strain.
(OA, Uruguay).
Trust in public or government health services varied across countries, but in all groups,
there was trust in general. Public services are seen as more reliable because they have historical
expertise and know-how, besides having greater resources than the private sector:
I’ve heard that the vaccine cold chain works better in the public health services than. . . in the
private services.
(ARF, Paraguay)
Some participants expressed that the vaccine in private health services might be of a better
quality than in their public counterparts, while also having shorter waiting times.
Health providers were by far the most common source of trusted information on vaccina-
tion across risk groups.
When the doctors explain things to me, I understand them better, and they told me: get your
shot for the flu, or else it will be very bad. And so that was it, I went and got the vaccine.
Really, that was the main reason I got the vaccine.
(MC, Uruguay).
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There are doctors who. . . tell you where you should go to get a vaccine–and they follow up on
you, they ask you if you’ve got your shot. This is why I believe this is the best vaccine, I feel con-
fident, I am sure that vaccines are good for everybody.
(ARF, Paraguay)
Despite being a trusted source of information, medical advice regarding the vaccine is not
always followed through. Reasons for not getting the vaccine in these cases are not due to a
lack of confidence and may be associated with factors regarding convenience and
complacency.
Another concern expressed with trust in the system was that vaccination program priorities
could be driven by pharmaceutical industry interests. In an extreme, some participants sus-
pected the pharmaceutical industry had financial gains with the process of updating influenza
strains. The commercial interest related to the vaccination programs raises doubts the credibil-
ity of vaccination program guidelines and of public health professionals’ advice:
I think [vaccination programs have a] pharmaceutical industry issue. I have a certain conspir-
acy theory, but then it’s something of mine. . . I read about it. . . I also think that the pharma-
ceutical industry promotes so many tests–they test, test, test. It seems to me that [virus strains]
could be something that laboratories develops.
(PW, Brazil).
It is a business of the laboratories that treat us like guinea pigs.
(OA, Uruguay).
Comparing the perception of confidence across countries, more often questioning of vac-
cine effectiveness was expressed in Paraguay than in other countries across risk groups. In this
country participants reported commonly the use of traditional medicine and herbs in the pre-
vention of influenza and for the treatment of disease symptoms, a qualitative association that
suggests that trust in traditional medicine could rival trust in the vaccine Participants from
Brazil, Paraguay, Peru and Uruguay questioned vaccine effectiveness only in the case of some
risk groups, especially mothers of young children.
Participants from all risk groups in Chile expressed positive views about vaccine safety. In
Paraguay, by contrast, the idea that the vaccine can cause the disease was widespread. In
Peru and Brazil, mistrust concerning the safety of the vaccine occurs more among adults
with comorbidities, while in Brazil questions arose about the safety of the vaccine during
pregnancy. Greatest distrust in the health system was expressed in Paraguay, especially
regarding the view that the vaccine is, in general, offered late. Related to this, participants in
this country expressed more trust in traditional medicine and in pharmacies than partici-
pants from other countries. In Uruguay and Brazil, participants in some risk groups, partic-
ularly adults with comorbidities and pregnant women, say that doctors have different
positions concerning vaccine recommendation, raising doubts about the safety of the
vaccine.
Complacency: Influenza risk and severity
Influenza was perceived by most risk groups as a serious illness, aggravated by the fact that
there are no pharmaceutical cures and that it may be life-threatening (Table 3).
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[Influenza is of] high risk, a person can die. My niece got sick last year and badly, [she had]
seizures, high fever. [She was given] very expensive antibiotics and was hospitalized.
(ARF, Chile).
And curing the flu, it does not cure; it has its process, you can alleviate the symptoms with all
that is sold in the market.
(OA, Uruguay).
Pregnant women were most ambiguous in discussing the risks regarding the vaccine and
the disease. Some participants argued that it would be best to take the vaccine, because if they
had the flu they would have limited options due to drug contraindications during pregnancy:
Not being pregnant, I can take anything. . . But now I know I can’t. I think that’s why [I got
vaccinated], I don’t know if I’m going to give it to myself next year. [Pregnancy] is like a stage
where I feel more vulnerable in health.
(PW, Uruguay).
It seems that [influenza] is stronger in pregnancy, they told me that I had to be vaccinated. . .
since I cannot take anything.
(PW, Chile).
Other pregnant women perceived influenza with ambivalence with respect to its severity:
I think influenza can be easily cured. . . I don’t know anyone close to me with a flu that knocks
you down. But from everything I’ve read about it, influenza can be very complicated, there are
cases of death. But in my family environment and in my work, I work in a salon, it is not very
big and there has never been a case of someone who had to be bedridden.
(PW, Brazil)
Confusion between influenza and other respiratory diseases led also to complacency, where
influenza is seen as a cold (resfriado) with more intense symptoms or as a complication of a
common cold:
Influenza is like a kind of flu [gripa], a variety of flu so to speak that it can be contracted [if
the person has] low defenses or is poorly cured of the flu.
(PW, Peru).
It is a flu disease that, when not cared for, can become pneumonia, it has more risks and it is a
little difficult to cure and that is why you have to be vaccinated every year.
(ARF, Peru).
Let them tell us the specific benefits of the vaccine; we do not know in writing what the benefits
are [for children]. Not catching the flu, but what else? Maybe it is also useful for respiratory
infections, to make them milder, I don’t know, anyway. [We need] something that one can
read, short and clear, not technical information.
(MC, Uruguay).
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Individuals did not perceive themselves to be in a special risk category, except in a few instances
with pregnant women–as seen above–and with older adults. Rather, everyone is deemed equally
exposed to contracting influenza. Among mothers, what makes children vulnerable to catching
influenza are certain behaviors, such as walking barefoot or going out without proper clothing:
It’s impossible to avoid [the flu] with children. . . children will be children! They go about in
their bare feet, they drink ice cold water, they don’t want to put on proper clothes. Not even
socks, even when its winter!
(MC, Brazil).
Complacency: Alternatives for prevention and treatment
All risk groups expressed that there are multiple ways of preventing influenza besides the vac-
cine, although the vaccine was perceived as the most important, clearly so by mothers and
pregnant women (Table 4).
I have many measures that I had to follow with my son [such as] when the air is very bad not
taking him to public places. . . But the vaccine is the most important, because. . . [children] at
school don’t remember to keep washing their hands, and there are many bugs there, but the
vaccine is always [effective].
(MC, Chile).
Influenza can be prevented, if you are careful enough with what you take, taking care not to
infect others and [that they] not to infect you, of course you need vaccinations and that is a
way of prevention.
(PW, Peru).
Healthy food and hygiene are commonly mentioned as complementary to vaccination, but
also as substitutes:
I think that obviously a healthy diet with vitamin C is undeniable that helps us to be pre-
pared. . . I can prevent it staying in my house, not being in crowded environments, especially
washing my hands after riding buses, taxis, supermarkets. I think you can warn others if you
are sick, not receive visits, not visit anyone.
(OA, Uruguay).
I don’t much like vaccines in themselves. . . Because I feel that they are not a very natural
thing, the body itself has its defenses and one can protect oneself through food.
(PW, Chile)
Elderly adults and mothers expressed that you could mitigate some influenza symptoms;
this, in turn, may moderate risk perception and induce alternative preventive actions.
A home remedy, a good lemon tea with honey and a splash of alcohol, so that the body
perspires, relieves itchy throat, a couple of anti-flu [medications] and do not go out to the cold.
(OA, Uruguay).
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Comparing the perception of complacency with influenza across countries, adults with
risk factors in Uruguay perceived themselves as particularly vulnerable. With regard to
pregnant women, in Brazil, Paraguay and Uruguay they did not see themselves as particu-
larly vulnerable to the flu, as against Chile and Peru where vulnerability was clearly
expressed. Participants across risk groups from Paraguay believed influenza can be cured, a
perception that could compete with that of vaccines as an alternative to address the disease.
Participants from Paraguay and Uruguay privileged behavioral measures for prevention of
influenza such as hygiene and diet as well as home or traditional remedies. In Uruguay,
pregnant women were more willing to take the vaccine because they anticipate they will
have limited resources if they eventually fall ill, considering restrictions due to their
pregnancy.
Convenience: Availability and geographical accessibility
All risk groups perceived relatively good access to influenza vaccination in general. The vac-
cine is referred as available within health facilities during campaigns.
You can get [the shot] anywhere, when they launch the national campaign. . . You have to
look for the schedules and see when its best for you. It is easy to access.
(MC, Uruguay).
In Brazil there was consensus among all risk groups regarding availability and ease of access
in public health services with the health system, the Sistema Único de Saúde (SUS). However,
mothers complained of closures of those facilities outside the health system that no longer
offered the vaccines as well as changes in primary health daily operations:
Schools and day care centers used to [provide the vaccine,] not anymore. . . It used to be that
in the past there were community agents who went to the houses. Now you have to go to the
clinic to give the children a vaccine.
(MC, Brazil).
The campaigns are limited in their duration and target those most vulnerable to influenza.
This in turn results in difficulties when the population seek the vaccine outside of the cam-
paign period.
I went to the vaccination post and I did not find the vaccine. . . The vaccine should be given all
year round [in public facilities], because otherwise the ones that commercialize the vaccines
are the clinics, the private [businesses].
(ARF, Peru).
Even during the campaign, there were some complaints of stock-outs, but these were not
shared by most participants.
[The vaccine] ends quickly and you need time to go; most [of us] work, to get a leave is very
complicated because you have to estimate [when] you will have to go again.
(MC, Paraguay).
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The mutualists [health providers] ran out of doses very quickly. This time I got it at a poly-
clinic at the municipality, which was also [open] in specific days.
(PW, Uruguay).
The campaign duration seems to be too short for many who want to use these health ser-
vices. There were complaints regarding vaccine services scheduling restrictions, especially for
participants who work throughout the day and find it difficult to attend health services.
In Brazil expressions were prominent regarding access restrictions for specific risk groups,
and the putting in place of stratagems to gain access and avoid payment of private providers:
You have to bring your child, then on that day you pay for public transport. . . Then, you have
to pay [again if you did not find it the first time] for public transport for one, for two. . . That’s
why it is good to [make the vaccine available] to everyone.
(OA, Brazil).
I lied that I had asthma and bronchitis to be able to get [the vaccine] at the clinic, because oth-
erwise I would have to pay. And we are not able to pay for a vaccine.
(PW, Brazil).
Confusion was manifested between seasonal and on-demand vaccination schedules:
This flu vaccine is. . . it only on campaign, on campaign day, or at the clinic? Because I think
it should be not only [available] on campaign days. . . in the children’s [vaccination] card
there are all doses, but there should also be H1N1 as well.
(MC, Brazil).
Focus group participants across all countries highlighted that there are no problems regard-
ing access to the influenza vaccine during campaign periods and for priority risk groups. They
know where to get the vaccine and, in general, health services are close by and easily accessible.
Convenience: Affordability and willingness-to-pay
The vaccine was generally perceived as free at the point of delivery in government facilities
during the campaigns, but expensive in private facilities:
The vaccine for those who are [cared for by] private [providers] is expensive. . . More than 100
reais (U$25), [or even] 180 reais (U$45). So many people don’t do it due to the lack of funds.
(OA Brazil).
They did not charge me because it was in the campaign, so it was free at the public health ser-
vices . . . I always go during the campaigns, because it is free.
(OA, Peru)
Influenza vaccine was generally perceived as accessible from the economic perspective in all
countries, with participants reporting that it could be obtained free of charge within public
health facilities.
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Convenience: Understanding and appeal
All groups except adults with risk factors complained of a lack of information on the vaccine
and its availability.
There is no certain information that in such a place they can go whenever they want [to be
vaccinated].
(PW, Uruguay).
The little vaccine information is mostly reported to be received across risk groups from vac-
cination campaigns and health posts.
I have a health service five minutes from my house and they usually go out to campaign, they
inform you, they leave you the brochures and they. . . give you the vaccine and everything.
(PW, Peru).
In the public health services, I got my shot quickly. This last time I went to a clinic of the
municipal government, it was in specific days of the week. Maybe they offer the vaccine in
other places, but there really isn’t any clear information about what places to go or when we
can go.
(PW, Uruguay)
In Brazil older adults and pregnant women recognized themselves as being privileged
groups. Older adults are treated as campaign priority and are stimulated by health providers to
get their vaccine in their routine consultations. The subject of vaccines is also brought up by
health professionals during prenatal care.
I always take the influenza vaccine, every year I get my shot. . . it’s just wonderful. I leave the
clinic happy, because I already got my shot. I feel really great.
(OA, Brazil)
In some cases, telephone reminders were mentioned as facilitators. Access to insurance was
also a facilitator of convenience:
My mom gets [the influenza vaccine] every year in the doctor’s office; they call her on the
phone and tell her that she has to get vaccinated on that day.
(ARF, Chile).
As I have insurance, they know that I am lacking the vaccine and they simply tell me ’sir, you
need to be vaccinated for influenza’ and they. . . vaccinate me.
(OA, Peru).
Comparing the convenience of the influenza vaccine across countries, participants from
Paraguay expressed least knowledge about influenza and the vaccine. Participants from Chile,
on the other hand, expressed a higher level of knowledge. In other countries, participants
expressed the need the have more information on the disease and on the vaccine.
PLOS ONE Influenza vaccination hesitancy in five countries of South America
PLOS ONE | https://doi.org/10.1371/journal.pone.0256040 August 12, 2021 16 / 23
Discussion
To our knowledge, this paper analyzes for the first time the range of knowledge, attitudes and
practices expressed with respect to influenza vaccine hesitancy by members of high-risk groups
living in large urban areas of countries in South America. In Latin America the only previous
qualitative studies on influenza vaccine hesitancy focused on Peru [16], while studies in Brazil
have focused on pediatric vaccine hesitancy [17].
Our results suggest that confidence is the most important construct associated with influ-
enza vaccine hesitancy across the four risk groups, mostly through perceptions of mistrust in
vaccine safety and effectiveness and, to a lesser extent, mistrust in the health system (Fig 1).
Moreover, some groups expressed the fear that the vaccine itself might pose risks, having side
effects, specially to those who were thought to be in a vulnerable condition, such as pregnant
women and adults with risk factors, a perception that was particularly acute in Brazil. Our
study suggests that confidence in the vaccine in the five countries studied and across risk
groups was higher in Chile and lower in Paraguay, with marked contrasts regarding vaccine
effectiveness, safety, and trust in the health system. Both our qualitative and quantitative results
are congruent with the national influenza vaccination rates observed across countries, where
Fig 1. Most important influenza complacency and vaccine confidence issues across risk groups and countries.
Confidence and complacency may be reinforcing and lead to a positive situation of high confidence and low
complacency as clearly observed among older adults and across risk groups in Chile. A less positive situation can be
observed among adults with risk factors, followed by mothers of infants and pregnant women, and by across risk groups
in Paraguay. Risk groups: ARF Adults with risk factors, MC Mothers of children under 6 years of age, OA Older adults,
PW Pregnant women. Countries shown: CH Chile, PA Paraguay.
https://doi.org/10.1371/journal.pone.0256040.g001
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Brazil and Chile have considerably higher uptake for all risk groups as against Paraguay and
Uruguay, and also to a lesser extent in comparison to Peru (Table 5).
Focus group participants generally expressed trust in their health care providers, with
exceptions in Paraguay. Even when they had doubts about the vaccine, their confidence in
health professionals leads them to gain confidence in the vaccine. However, the medical advice
was perceived as ambiguous across risk groups, expressing that sometimes they were
instructed to be vaccinated, others not.
Our study also suggests that less information or knowledge is associated to a greater mis-
trust of the vaccine. Paraguay stands out as a country where focus group participants had very
little knowledge of both the disease and the vaccine.
The importance of confidence as a factor in vaccine hesitancy was also observed by the sur-
vey arm of our study which obtained quantitative information on the 3Cs for the same risk
groups, countries and socioeconomic groups, reporting that individuals with a higher compos-
ite indicator of influenza vaccine confidence also had higher probability of being vaccinated in
the last year [15]. This study also suggested higher vaccine confidence and vaccine uptake lev-
els in Chile and lower in Paraguay and Uruguay, supporting the qualitative study results we
are now reporting.
Other studies in South America also evaluate confidence as the critical component of vac-
cine hesitancy. Brown et al. found among a survey sample in Brazil that the commonest rea-
sons for hesitancy were issues with confidence (41.4%), efficacy/safety of the vaccine (25.5%)
and concerns about adverse events (23.6%) [16]. Reinders and collaborators found in a ran-
domized household survey in urban areas near large hospitals in Peru that confidence and spe-
cifically “being afraid of vaccination and its effects” is the most critical factor behind influenza
vaccine hesitance. A world-wide systematic review of seasonal influenza vaccination intention
and behavior undertaken by WHO between 2005 and 2016 found confidence and specifically
Table 5. Influenza vaccination coverage by risk groups in selected countries of South America. 2018 or most recent year.
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a perceived low effectiveness of the vaccine as the most frequently reported reasons for hesi-
tancy across risk groups [16].
Complacency with not being vaccinated was found in our study to be also critical for vac-
cine acceptance, with a large and diversified set of perceptions such as the importance of a
healthy diet lowering the perception of influenza risks while providing alternatives for preven-
tion. We also found a low level of perception of at-risk individuals as members of a risk group,
except for older adults and to some extent adults with risk factors, especially those who had a
condition such as asthma. The tendency was to perceive greater risk in others, particularly
among pregnant women who perceive vaccination to be more important for their babies than
for themselves. Across countries, complacency of influenza was higher in Paraguay and Uru-
guay than in other countries, possibly due to the high value given in these countries to tradi-
tional measures to prevent illness, a situation that could take the vaccine out of the spotlight or
relegate as a secondary preventive measure.
Our data indicate that confidence and complacency are intimately related. We found that
complacency with the risks posed by influenza in the context of trust in traditional medicine
and distrust in the health system–as observed for the case of Paraguay–was associated to a per-
ception of side-effects and even of the view that the vaccine can cause influenza. Furthermore,
our study suggests, as in the case of older adults, that low levels of complacency with influenza
risks can support higher levels of confidence in the vaccine. These possible associations across
confidence and complacency require further research to ascertain cognitive and affective links.
In our study, less information and knowledge regarding influenza and the vaccine are quali-
tatively related to a greater mistrust of vaccination. Focus group participants from Paraguay
expressed the most doubts on both topics. The more people distrust the vaccine, the more they
will have recourse to traditional or alternative strategies to prevent influenza, such as diet,
hygiene, clothing, environment. Those who do not perceive influenza to be a serious or life-
threatening disease tend to be more vaccine hesitant.
Findings on confidence and complacency point to the importance of health promotion and
communication strategies to improve knowledge about influenza risks and to establish that
hygiene measures do not replace vaccination. While all risk groups acknowledged that influ-
enza could be a potentially mortal disease, they also expressed confusion between influenza
and other respiratory infections. In this sense, influenza is seen either as a complication of the
common cold or as something very prevalent–ordinary even–posing a small threat to the
health of most people who have it.
Reinders and collaborators found particularly low levels of self-perception of pregnant
women and older adults as high-risk groups for influenza in Peru [16]. The perception of indi-
viduals as belonging to risk groups can be enhanced through conditioning social program ben-
efits, as in the case of children in Brazil, where having a vaccination card up to date is a
requirement to receive Bolsa Famı́lia, a government program for income redistribution [18].
For the past decades, social scientists have discussed how different Explanatory Models
(EM) for a disease are important for understanding how individuals explain their causes,
symptoms, and treatments, and hence for the role of complacency in vaccine hesitancy. The
flu and the common cold are associated by participants to feeling cold or exposing parts of the
body to lower temperatures (bare feet specially), and prevention involves dressing warmly or
consuming warm foods and liquids. A healthy diet is cited by participants as another impor-
tant preventive measure, and that involves consuming fruits rich with vitamin C or associated
with boosting the immune system. In our findings, influenza vaccination is perceived as com-
peting with other practices that are also considered preventative, whether by themselves or as
complements to vaccination. Mothers of young children and pregnant women tend to over
rely on hygiene and a healthy diet–which are unquestionably positive for pregnancy and child
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development–as preventative of influenza. For the older adults and adults with risk factors,
their perceived vulnerability to influenza may be associated with the observed expressions of
interest in vaccination, making them less complacent. Future studies focusing on folk medi-
cine and existing EM for the flu and the cold in urban contexts of Latin America would be
important to expand on our findings [19, 20].
Our study suggests that individuals belonging to specific risk groups for influenza lack
examples of the severity and hence the uniqueness of influenza, possibly due to the paradoxical
effects of vaccination programs as they reduce mortality. The exception were older adults, who
had both more personal experience with the vaccine and knew someone who had been terribly
ill due to influenza. Reinders and collaborators found greater vaccination rates among persons
who perceived the severity of influenza in Peru [16]. Our survey study found complacency to
be the component of the 3C model with the weakest evaluation given prejudices, knowledge
and risk perception. However, as mentioned already, complacency was not as strongly associ-
ated with vaccination rates as confidence was. Further afield, in Australia extreme events lived
by communities pivoted parental responsibility for child vaccination [21].
The convenience of influenza vaccination was the most positively evaluated component in
our study, both across risk groups and countries. None-the-less, perceptions on restrictions
with information, particularly in Brazil, were observed, while opportunities to improve access
were found across all risk groups and countries. Perceptions of program appeal were not so
much negative as absent, together with examples of negative appeal in terms of possible disre-
spectful and culturally inappropriate treatment of indigenous population in Peru, as found for
health care in general for indigenous populations in other countries [22, 23]. In another arm
of our research, we explored the balance given by country influenza vaccination programs to
strategies focused on increasing confidence and convenience and on lowering complacency
[24]. Congruent with the qualitative findings, we found that programs across the five countries
privilege convenience through supply-side strategies. Our qualitative findings suggest the need
for influenza vaccination programs to address confidence and complacency through directed
strategies.
A limitation of our qualitative research is its primary focus on the situation of vaccine hesi-
tancy within risk groups rather than at the country level. Furthermore, our results cannot be
generalized to urban populations across countries, given the primary aim of the research of
identifying qualitative patterns. Even so, our sample aimed to include countries with both high
performing vaccine programs (Brazil and Chile) and low-performing programs (Paraguay,
Peru and Uruguay, see Table 5). A possible limitation of the focus group technique employed
is that it could have inhibited responses that differed markedly from those held by the majority
of the participants.
In spite of the limitations stated, our analysis did suggest that influenza vaccination hesi-
tancy has greater similarities than differences across the countries studied, possibly due to sim-
ilar social, health system and cultural characteristics, as in our analysis of national vaccination
programs [24].
The specific findings regarding each of the 3Cs in the vaccine hesitancy model across risk
groups and countries provide valuable information for program planning and to guide inter-
sectoral policies and strategies. Given that vaccine convenience perceptions are structured and
focused on limited problems, efforts to improve this dimension of hesitancy can be readily
implemented and can support strategies to improve confidence and complacency. Effective
and assertive communication strategies can be developed to target specific risk groups and
health workers involved in vaccination. Messages should emphasize the risks posed by influ-
enza and the benefits of being vaccinated, and these messages need to be divulged all year, not
only during the influenza vaccination campaigns. Spokespersons can be designated and
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trained to demonstrate the value of vaccination as well as to solve all vaccination doubts
through interactive, digital-based media as available. However, vaccine hesitancy is very often
based on emotional responses and countering emotion with reason (e.g. unbiased informa-
tion) typically doesn’t work [24]. Bolstering vaccine confidence on the basis of emotive as well
as rational concepts adapted to specific risk groups should therefore be the top priority to
reduce hesitancy. Given that the most trusted sources of information are health professionals,
efforts should be made to provide them with training, incentives and tools focusing on the
needs and sensibilities of specific risk groups. Three groups of actions have been proposed:
addressing opportunities to modify confidence in vaccine effectiveness and concerns about
safety; bolstering altruism in specific social contexts through normative messaging; and pivot-
ing change in health professionals through incentives, sanctions and requirements [25, 26].
Communication strategies must be precise to avoid counterproductive results which could
lead to reinforcing hesitation to vaccination [27].
The fact that focus group participants across risk groups from Paraguay and Uruguay
expressed greater influenza vaccine hesitancy suggest the importance of further analyzing
country-specific factors such as the reliance on traditional medicine as well as differences in
health system trust.
The COVID-19 pandemic will likely affect uptake for seasonal influenza vaccination
given changes in risk perception associated with mortality and economic impact of viral
respiratory diseases [28]. Influenza vaccination has been recommended to reduce hospitali-
zations and relieve resources to care for COVID-19. The COVID-19 vaccine may also alter
seasonal influenza vaccination programs and influenza vaccine uptake. Seasonal influenza
vaccination in Brazil was anticipated one month in March 2020 to help reduce respiratory
diseases and help to cope with COVID-19. It is important to prepare for COVID-19 vaccina-
tion addressing lessons with influenza vaccine hesitancy. Influenza and COVID-19 vaccina-
tion strategies may converge in the future so our findings can be useful to prepare for such a
scenario.
Conclusions
The study of influenza vaccine hesitancy in five countries of South America revealed a wide
range of perceptions regarding confidence and complacency across risk groups and, to a
lesser extent, across countries. While risk groups share some common perceptions, they also
have specific conceptions that present intervention opportunities. Information and commu-
nication strategies need to be tailored for specific risk groups to address their concerns and
the take advantage of their varied relationship to health providers. Country-specific mea-
sures should consider contextual factors. Confidence and complacency should be addressed
in their own right, through strategies that can increase one while reducing the other, in
synergy.
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